Brand name · Autoimmune / Anti-TNF
Remicade (Infliximab) J-Code / HCPCS Code
In short
Remicade is billed under HCPCS J1745 — Injection, infliximab, excludes biosimilar, 10 mg. One billing unit is 10 mg.
Infliximab biosimilars have their own HCPCS codes.
Reference
- Code
- J1745 — Injection, infliximab, excludes biosimilar, 10 mgMed-Code curated
- Billing unit
- 10 mg
- Same code in the directory
- Infliximab
- Pharmacologic class
- Tumor Necrosis Factor BlockerFrom the FDA listings below
- Labelers
- Janssen Biotech, Inc.
- J-code category
- Autoimmune / Anti-TNF
FDA-listed products
Finished products whose name and route match this directory entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Remicadeinfliximab | Infliximab 100 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | Janssen Biotech, Inc. | 57894-030 |
NDCs billed under J1745
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 2 NDCs to J1745 for Infliximab and Remicade. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Infliximab | 57894-0160-01 | Janssen Biotech, Inc. | 1 | 10 |
| Remicade | 57894-0030-01 | Janssen Biotech, Inc. | 1 | 10 |